Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations
Rituximab is a chimeric (mouse and human) monoclonal antibody against B-lymphocytes (CD20). This drug is widely used in rheumatology in the treatment of rheumatoid arthritis, Sjogren’s syndrome, some systemic connective tissue diseases and vasculitis, as well as in hematology in lymphoproliferative...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2023-10-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3410 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240264120467456 |
|---|---|
| author | T. S. Panevin E. G. Zotkin E. A. Troshina G. V. Lukina |
| author_facet | T. S. Panevin E. G. Zotkin E. A. Troshina G. V. Lukina |
| author_sort | T. S. Panevin |
| collection | DOAJ |
| description | Rituximab is a chimeric (mouse and human) monoclonal antibody against B-lymphocytes (CD20). This drug is widely used in rheumatology in the treatment of rheumatoid arthritis, Sjogren’s syndrome, some systemic connective tissue diseases and vasculitis, as well as in hematology in lymphoproliferative diseases. Administration of rituximab leads to depletion of B-lymphocytes through various mechanisms, including antibody-dependent and complementdependent cytotoxic effects, as well as the regulation of apoptosis. Considering the mechanism of autoimmune damage in Graves’ disease, an autoimmune thyroid disease accompanied by thyrotoxicosis and endocrine ophthalmopathy (an autoimmune lesion of the accessory apparatus of the eye), the use of rituximab may be effective in these diseases. The review considers the currently available results of studies on the use of various doses of rituximab in these diseases. |
| format | Article |
| id | doaj-art-e8ff66be35b1465cbb631b4ad2812b6b |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2023-10-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-e8ff66be35b1465cbb631b4ad2812b6b2025-08-20T04:00:40ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922023-10-0161554555310.47360/1995-4484-2023-545-5532930Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitationsT. S. Panevin0E. G. Zotkin1E. A. Troshina2G. V. Lukina3V.A. Nasonova Research Institute of Rheumatology; Far Eastern State Medical UniversityV.A. Nasonova Research Institute of RheumatologyNational Medical Research Center for EndocrinologyV.A. Nasonova Research Institute of Rheumatology; Loginov Moscow Clinical Scientific CenterRituximab is a chimeric (mouse and human) monoclonal antibody against B-lymphocytes (CD20). This drug is widely used in rheumatology in the treatment of rheumatoid arthritis, Sjogren’s syndrome, some systemic connective tissue diseases and vasculitis, as well as in hematology in lymphoproliferative diseases. Administration of rituximab leads to depletion of B-lymphocytes through various mechanisms, including antibody-dependent and complementdependent cytotoxic effects, as well as the regulation of apoptosis. Considering the mechanism of autoimmune damage in Graves’ disease, an autoimmune thyroid disease accompanied by thyrotoxicosis and endocrine ophthalmopathy (an autoimmune lesion of the accessory apparatus of the eye), the use of rituximab may be effective in these diseases. The review considers the currently available results of studies on the use of various doses of rituximab in these diseases.https://rsp.mediar-press.net/rsp/article/view/3410rituximabgraves’ diseasediffuse toxic goiterendocrine ophthalmopathy |
| spellingShingle | T. S. Panevin E. G. Zotkin E. A. Troshina G. V. Lukina Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations Научно-практическая ревматология rituximab graves’ disease diffuse toxic goiter endocrine ophthalmopathy |
| title | Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations |
| title_full | Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations |
| title_fullStr | Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations |
| title_full_unstemmed | Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations |
| title_short | Rituximab in the treatment of Graves’ disease and endocrine ophthalmopathy. Opportunities and limitations |
| title_sort | rituximab in the treatment of graves disease and endocrine ophthalmopathy opportunities and limitations |
| topic | rituximab graves’ disease diffuse toxic goiter endocrine ophthalmopathy |
| url | https://rsp.mediar-press.net/rsp/article/view/3410 |
| work_keys_str_mv | AT tspanevin rituximabinthetreatmentofgravesdiseaseandendocrineophthalmopathyopportunitiesandlimitations AT egzotkin rituximabinthetreatmentofgravesdiseaseandendocrineophthalmopathyopportunitiesandlimitations AT eatroshina rituximabinthetreatmentofgravesdiseaseandendocrineophthalmopathyopportunitiesandlimitations AT gvlukina rituximabinthetreatmentofgravesdiseaseandendocrineophthalmopathyopportunitiesandlimitations |